Ivana Gojo MD

Associate Professor of Oncology, Johns Hopkins University School of Medicine; Associate Professor of Oncology, Co-Director, Leukemia Drug Development Program

Join to View Full Profile

401 North Broadway StreetWeinberg BLDGBaltimore, MD 21287
Phone+1 410-955-8964
Fax+1 410-367-2194

Education & Training

University of MarylandFellowship, Hematology and Medical Oncology, 1998 - 2001
Zucker School of Medicine at Hofstra/Northwell at Lenox Hill HospitalResidency, Internal Medicine, 1995 - 1998
University of Zagreb Faculty of MedicineClass of 1992

Certifications & Licensure

MD State Medical License 2001 - 2026
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes Start of enrollment: 2005 Dec 01
Completed
Phase 1
Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia Start of enrollment: 2010 Apr 01
Completed
Phase 1
Veliparib and Temozolomide in Treating Patients With Acute Leukemia Start of enrollment: 2010 May 21
ACTIVE_NOT_RECRUITING
PHASE1
Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Start of enrollment: 2013 Dec 16
Completed
Phase 1
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia Start of enrollment: 2017 Oct 25
ACTIVE_NOT_RECRUITING
PHASE1
Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML Start of enrollment: 2016 Aug 11
Completed
Phase 1
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance Start of enrollment: 2017 Sep 05
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients Start of enrollment: 2023 Jul 06
ACTIVE_NOT_RECRUITING
PHASE1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML.
Andrew D Zale, Venkata Preetam Sandeep Kaduluri, Jonathan A Webster, Mark J Levis, Ivana Gojo
Blood Neoplasia. 2025-11-01
Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities.
J Preston Claiborne, Daniel Li, Hua-Ling Tsai, Gabriel Ghiaur, B Douglas Smith
Leukemia Research. 2025-10-01
C-C motif chemokine receptor-like 2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated.
Nour Sabiha Naji, Sergiu Pasca, Theodora Chatzilygeroudi, Pablo Toledano-Sanz, Joseph Rimando
Haematologica. 2025-08-28

Journal Articles

Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Ri...
Joshua F Zeidner, Mark R Litzow, Jeffrey E Lancet, Prithviraj Bose, Raoul Tibes, Ivana Gojo, Richard F Little, Judith E Karp, Leukemia Research

Abstracts/Posters

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)Clinicall...
Ivana Gojo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume Leukapheresis
Ivana Gojo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or M...
Ivana Gojo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML
Ivana Gojo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Authored Content

Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Risk Acute Myeloid Leukemia (AML)August 2018